Reliance Industries has multiple catalysts, 20% upside potential: JPMorgan
JPMorgan believes the $45 billion worth of investments and capex across business verticals to be fully value accretive by FY25. This is not priced in by the current stock price which offers an attractive risk-reward, the brokerage said.
Mankind Pharma rallies 32% on day 1
At Tuesday’s closing price, Mankind Pharma was valued at a price-to-earnings ratio of 43 times its FY22 earnings. Mankind is now India’s fifth largest pharma company by market value of ₹57,046 crore. Sun Pharma, Divi’s Lab, Dr. Reddy’s Lab, and Cipla are currently valued between ₹75,284 crore and ₹2.31 lakh crore.